Teacher Retirement System of Texas decreased its position in Diplomat Pharmacy Inc (NYSE:DPLO) by 34.7% during the 1st quarter, Holdings Channel reports. The firm owned 10,668 shares of the company’s stock after selling 5,665 shares during the period. Teacher Retirement System of Texas’ holdings in Diplomat Pharmacy were worth $215,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of DPLO. Schwab Charles Investment Management Inc. lifted its position in shares of Diplomat Pharmacy by 19.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 351,592 shares of the company’s stock worth $7,057,000 after acquiring an additional 57,095 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Diplomat Pharmacy by 26.3% during the fourth quarter. Wells Fargo & Company MN now owns 90,104 shares of the company’s stock worth $1,809,000 after acquiring an additional 18,743 shares in the last quarter. D.A. Davidson & CO. purchased a new stake in shares of Diplomat Pharmacy during the fourth quarter worth $278,000. State of Wisconsin Investment Board lifted its position in shares of Diplomat Pharmacy by 43.9% during the fourth quarter. State of Wisconsin Investment Board now owns 328,000 shares of the company’s stock worth $6,583,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Diplomat Pharmacy by 226.7% during the fourth quarter. Arizona State Retirement System now owns 81,033 shares of the company’s stock worth $1,626,000 after acquiring an additional 56,233 shares in the last quarter. Institutional investors and hedge funds own 75.66% of the company’s stock.
Shares of DPLO stock opened at $28.13 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.57 and a debt-to-equity ratio of 0.59. Diplomat Pharmacy Inc has a 52-week low of $14.23 and a 52-week high of $28.74. The firm has a market capitalization of $2.09 billion, a P/E ratio of 31.97 and a beta of 1.33.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, May 7th. The company reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the business posted $0.19 EPS. The company’s quarterly revenue was up 24.4% on a year-over-year basis. analysts predict that Diplomat Pharmacy Inc will post 0.92 EPS for the current year.
In related news, Director Shawn Tomasello sold 1,680 shares of the stock in a transaction on Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total value of $40,773.60. Following the sale, the director now owns 12,816 shares in the company, valued at $311,044.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey G. Park sold 13,875 shares of the stock in a transaction on Wednesday, May 23rd. The stock was sold at an average price of $24.20, for a total value of $335,775.00. The disclosure for this sale can be found here. Insiders sold 17,250 shares of company stock worth $419,364 in the last quarter. 24.70% of the stock is currently owned by company insiders.
Several equities research analysts have issued reports on DPLO shares. Leerink Swann set a $30.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Wells Fargo & Co restated a “market perform” rating and set a $25.00 target price (up previously from $21.50) on shares of Diplomat Pharmacy in a research report on Tuesday, February 27th. Needham & Company LLC set a $28.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Deutsche Bank upgraded Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, Barclays started coverage on Diplomat Pharmacy in a research report on Thursday, March 8th. They set an “overweight” rating and a $27.00 target price on the stock. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Diplomat Pharmacy presently has an average rating of “Buy” and an average target price of $27.20.
Diplomat Pharmacy Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.